TCTR20210722003招募中2 期
Immune response of booster dose with ChAdOx-1 in adult who had received 2 doses of CoronaVac (COVID-19)
Health and Aging Platform, Chulalongkorn University0 个研究点目标入组 400 人开始时间: 2021年7月22日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 59 Years（—）
- 性别
- All
入选标准
- •1. Age 18-59 years
- •2. Have a history of receiving two doses of CoronaVac vaccine with 21-28 days apart.
- •3. Post-second dose of CoronaVac vaccine for more than 60-180 days on day of participation in study
排除标准
- •1. Received immunosuppressants within 3 months prior to participation in the study
- •2. Received blood or blood products within 3 months prior to participation in the study
- •3. Received any vaccinations within 2 weeks prior to participation in the study
研究者
相似试验
招募中
不适用
Evaluation of the humoral response to COVID-19 vaccines in BrazilRNA Virus InfectionsAntibody FormationImmunogenicity, VaccineB34.2RBR-33ndb47Fundação Oswaldo Cruz
已完成
4 期
Immunogenicity and safety of ChAdOx1 vaccine (Covid-19 vaccine) in Thai people with underlying diseaseDiabetes mellitusCirrhosissolid cancerHematologic malignancychronic kidney diseaserheumatological diseasecardiovascular diseaseChAdOx1 vaccineimmunogenicitycovid-19 vaccineTCTR20211228003Chulabhorn Royal Academy385
招募中
不适用
Comparison of the Immunogenicity of ChAdOx1 nCoV-19 (COVID-19) Vaccine against the Wild-Type and Delta Variant in Hemodialysis Patients and Healthy VolunteersImmune response after ChAdOx1 nCoV-19 Vaccine in hemodialysis patients compared to healthy volunteers.Immune response, ChAdOx1 nCoV-19 Vaccine, Hemodialysis patients, wild-type, delta variant, antibody, T-cell responseTCTR20211026002Kao Tun Roke Foundation130
招募中
不适用
Comparison of the Immunogenicity of ChAdOx1 nCoV-19 (COVID-19) Vaccine against the Wild-Type and Delta Variant in Kidney Transplant Recipients and Healthy VolunteersImmune response after ChAdOx1 nCoV-19 Vaccine in kidney transplant patients compared to healthy volunteers.Immune response, ChAdOx1 nCoV-19 Vaccine, kidney transplant patients, Wuhan Strain, B.1.617.2 (Delta) Variant, antibody, T-cell responseTCTR20211025004Kao Tun Roke Foundation200
尚未招募
2 期
ChAdOx1 Vaccine Dose-Sparing Strategies in Post COVID-19 patients: A Randomized Controlled TrialParticipants who recovered from COVID-19COVID-19 VaccineSARS-CoV-2AntibodyCellular immunityPost COVID-19intramuscularintradermalTCTR20211004005ational Research Council of Thailand (NRCT)360